FDA Announces Public Advisory Committee Meeting on Extended-Release/Long-Acting Opioid Analgesic Postmarketing Requirement

Summary

The FDA is hosting a joint meeting of its Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee to discuss a postmarketing requirement for extended-release/long-acting opioid analgesics, and is seeking public comments on the proposal.